11.07.26 -- Advancing RNA Newsletter Best Of October

NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

In the opening clip from this Advancing RNA Live event, AbbVie’s Elaine Peters, Sanofi’s Philippe Talaga, and Tessera’s Ilya Shestopalov share the novel methods they’ve been watching the most closely in the mRNA-LNP development space, as well as the role these methods will play in elucidating more about our drug products’ quality attributes. 

mRNA pipelines continue to advance, but has provider growth outpaced the pipeline? Let's take a closer look.

Stay ahead in mRNA therapeutic development by mastering the essential quality systems, process controls, and analytical methods required for robust GMP production and efficient manufacturing.

Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.

See how a continuous manufacturing platform streamlines production to days, uses real-time quality control, and dramatically cuts costs to accelerate access to new therapies.